A previous clinical study demonstrated that ipilimumab was efficacious in enhancing the therapeutic response when administered in conjunction with PD-L1 antibody in patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer [32,33]. The gene discussed is CD274; the disease is melanoma.